Wells Fargo & Company Affimed N.V. Transaction History

Wells Fargo & Company

$434 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	SELL	$0.32 - $0.62 $7,071 - $13,701	-22,099 Reduced 13.67%	139,514 $86,000
Q3 2023 Nov 13, 2023	SELL	$0.46 - $0.65 $6,631 - $9,370	-14,416 Reduced 8.19%	161,613 $77,000
Q2 2023 Aug 15, 2023	SELL	$0.57 - $1.08 $18,334 - $34,738	-32,165 Reduced 15.45%	176,029 $105,000
Q1 2023 May 12, 2023	BUY	$0.66 - $1.29 $26,533 - $51,860	40,202 Added 23.93%	208,194 $156,000
Q4 2022 Feb 13, 2023	SELL	$1.1 - $2.45 $4,877 - $10,863	-4,434 Reduced 2.57%	167,992 $208,000
Q3 2022 Nov 14, 2022	SELL	$1.96 - $3.32 $35,121 - $59,491	-17,919 Reduced 9.41%	172,426 $355,000
Q2 2022 Aug 12, 2022	SELL	$2.27 - $4.86 $90,128 - $192,961	-39,704 Reduced 17.26%	190,345 $527,000
Q1 2022 May 16, 2022	SELL	$3.69 - $5.65 $100,297 - $153,572	-27,181 Reduced 10.57%	230,049 $1.01 Million
Q4 2021 Feb 14, 2022	SELL	$5.37 - $7.07 $453,340 - $596,856	-84,421 Reduced 24.71%	257,230 $1.42 Million
Q3 2021 Nov 15, 2021	BUY	$5.54 - $7.51 $169,789 - $230,166	30,648 Added 9.85%	341,651 $2.11 Million
Q2 2021 Aug 16, 2021	SELL	$7.78 - $11.4 $374,949 - $549,411	-48,194 Reduced 13.42%	311,003 $2.64 Million
Q1 2021 May 13, 2021	BUY	$5.12 - $8.48 $965,309 - $1.6 Million	188,537 Added 110.48%	359,197 $2.84 Million
Q4 2020 Feb 09, 2021	SELL	$3.16 - $7.03 $116,771 - $259,779	-36,953 Reduced 17.8%	170,660 $994,000
Q3 2020 Nov 05, 2020	BUY	$3.26 - $4.73 $72,658 - $105,422	22,288 Added 12.03%	207,613 $704,000
Q2 2020 Aug 13, 2020	BUY	$1.58 - $4.63 $29,345 - $85,992	18,573 Added 11.14%	185,325 $855,000
Q1 2020 May 14, 2020	BUY	$1.44 - $3.02 $240,122 - $503,591	166,752 New	166,752 $263,000

Others Institutions Holding AFMD

# of Institutions

Shares Held

1.09M

Call Options Held

Put Options Held

View Full List

About Affimed N.V.

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $185M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

More about AFMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account